Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

(Reuters) -Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the ...

Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has ...

Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized ...

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...

Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.

Dec 3 (Reuters) - Biogen (BIIB.O), opens new tab expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company ...

Eisai (ESALY) and Biogen (BIIB) announced that the Federal ... anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” for the treatment of early Alzheimer’s disease.

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...